Liu Chenxi, Dai Xiaoming, Huang Wei
Department of Emergency Medicine, the First Affiliated Hospital of Dalian Medical University, Dalian 116012, Liaoning, China.
Department of Critical Care Medicine, the First Affiliated Hospital of Dalian Medical University, Dalian 116012, Liaoning, China. Corresponding author: Huang Wei, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Jan;33(1):5-9. doi: 10.3760/cma.j.cn121430-20201211-00749.
The main progress in international critical care medicine in 2020 are: the reflections on the mandatory of implementation of the 1-hour cluster treatment strategy for sepsis are still continuing; the "metabolic resuscitation" therapy, represented by large dose of vitamin C, failed to yield positive results; the global epidemic of coronavirus disease 2019 (COVID-19) continues to spread, with evidences indicating Dexamethasone, Remdesivir or interferon β-1b (IFNβ-1b), Lopinavir/Ritonavir and ribavirin as promising therapy; conservative oxygen therapy did not exert positive effects neither for mechanical ventilated patients nor for acute respiratory distress syndrome (ARDS) patient; the concept of lung- and diaphragm-protective mechanical ventilation illuminates a new opportunity to potentially improve clinical outcomes for critically ill patients; there was no positive evidence for stress ulcer prophylaxis and timing of endoscopy for severe acute upper gastrointestinal bleeding; early initiation of renal-replacement therapy (RRT) for critically ill patients with acute kidney injury (AKI) has not shown positive effect. At last, artificial intelligence (AI) has shown good potential in identifying ARDS phenotypes and early predicting sepsis.
2020年国际重症医学领域的主要进展包括:关于脓毒症实施1小时集束化治疗策略必要性的思考仍在继续;以大剂量维生素C为代表的“代谢复苏”疗法未取得阳性结果;2019冠状病毒病(COVID-19)在全球持续蔓延,有证据表明地塞米松、瑞德西韦或干扰素β-1b(IFNβ-1b)、洛匹那韦/利托那韦及利巴韦林是有前景的治疗方法;保守氧疗对机械通气患者和急性呼吸窘迫综合征(ARDS)患者均未产生积极效果;肺与膈肌保护性机械通气的概念为潜在改善危重症患者临床结局带来了新机遇;对于重症急性上消化道出血,应激性溃疡预防及内镜检查时机方面没有阳性证据;对急性肾损伤(AKI)危重症患者早期启动肾脏替代治疗(RRT)未显示出积极效果。最后,人工智能(AI)在识别ARDS表型和早期预测脓毒症方面显示出良好潜力。